Congress Passes Zika Funding Bill

Congress passed and President Obama signed a 10-week continuing resolution, which includes $1.1 billion for Zika virus research.

ASM Acts to Counter Zika Virus Outbreak

The emerging threat of Zika virus infection.

ASM Urges Action to Combat Zika Emergency

Current events linked to the Zika virus make aggressive public health actions and funding to combat this emerging infectious disease more crucial than ever.
Become a member today!
Submit Abstracts for Biothreats 2017
Antibacterial Development Conference

colley daniel


Dr. Colley is Director of the Center for Tropical and Emerging Global Diseases (CTEGD) and Director of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), as well as Professor of Microbiology at the University of Georgia.  His research is focused on both the immunology of human schistosomiasis and on operational research to find answers that will assist control program managers in countries endemic for schistosomiasis to better control and eliminate the disease.  His immunologic research efforts are now focused on human immune responses and immunoregulatory responses during schistosomiasis in western Kenya, where collaborates with Kenya Medical Research Institute (KEMRI) scientists Drs. Diana Karanja and Pauline Mwinzi, and his Centers for Disease Control and Prevention (CDC) colleague, Dr. W. Evan Secor.  Those studies have been ongoing for 17 years and involve cellular immunology research on school children and people occupationally exposed to the threat of schistosomiasis.  The research efforts of SCORE are being pursued in multiple sub-Saharan African countries and focus on how best to deliver praziquantel, the drug that is the major intervention for schistosomiasis control at this time, and how best to eliminate schistosomiasis in appropriate locations. In addition, SCORE is pursuing research on more appropriate diagnostics for schistosomiasis that will allow both increased ease of mapping for control programs and surveillance when prevalence gets low enough that surveillance is warranted.